| First Author | Bennion BG | Year | 2020 |
| Journal | Cell Rep | Volume | 31 |
| Issue | 11 | Pages | 107771 |
| PubMed ID | 32553167 | Mgi Jnum | J:291925 |
| Mgi Id | MGI:6445048 | Doi | 10.1016/j.celrep.2020.107771 |
| Citation | Bennion BG, et al. (2020) STING Gain-of-Function Disrupts Lymph Node Organogenesis and Innate Lymphoid Cell Development in Mice. Cell Rep 31(11):107771 |
| abstractText | STING gain-of-function causes autoimmunity and immunodeficiency in mice and STING-associated vasculopathy with onset in infancy (SAVI) in humans. Here, we report that STING gain-of-function in mice prevents development of lymph nodes and Peyer's patches. We show that the absence of secondary lymphoid organs is associated with diminished numbers of innate lymphoid cells (ILCs), including lymphoid tissue inducer (LTi) cells. Although wild-type (WT) alpha4beta7(+) progenitors differentiate efficiently into LTi cells, STING gain-of-function progenitors do not. Furthermore, STING gain-of-function impairs development of all types of ILCs. Patients with STING gain-of-function mutations have fewer ILCs, although they still have lymph nodes. In mice, expression of the STING mutant in RORgammaT-positive lineages prevents development of lymph nodes and reduces numbers of LTi cells. RORgammaT lineage-specific expression of STING gain-of-function also causes lung disease. Since RORgammaT is expressed exclusively in LTi cells during fetal development, our findings suggest that STING gain-of-function prevents lymph node organogenesis by reducing LTi cell numbers in mice. |
